Rectal Optical Markers for in Vivo Risk Stratification of Premalignant Colorectal Lesions

Andrew J. Radosevic, Nikhil N. Mutyal, Adam Eshein, The Quyen Nguyen, Bradley Gould, Jeremy D. Rogers, Michael J. Goldberg, Laura K. Bianchi, Eugene F. Yen, Vani Konda, Douglas Rex, Jacques Van Dam, Vadim Backman, Hemant K. Roy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Colorectal cancer remains the second leading cause of cancer deaths in the United States despite being eminently preventable by colonoscopy via removal of premalignant adenomas. In order to more effectively reduce colorectal cancer mortality, improved screening paradigms are needed. Our group pioneered the use of low-coherence enhanced backscattering (LEBS) spectroscopy to detect the presence of adenomas throughout the colon via optical interrogation of the rectal mucosa. In a previous ex vivo biopsy study of 219 patients, LEBS demonstrated excellent diagnostic potential with 89.5% accuracy for advanced adenomas. The objective of the current cross-sectional study is to assess the viability of rectal LEBS in vivo. Experimental Design: Measurements from 619 patients were taken using a minimally invasive 3.4-mm diameter LEBS probe introduced into the rectum via anoscope or direct insertion, requiring approximately 1 minute from probe insertion to withdrawal. The diagnostic LEBS marker was formed as a logistic regression of the optical reduced scattering coefficient μs and mass density distribution factor D. Results: The rectal LEBS marker was significantly altered in patients harboring advanced adenomas and multiple nonadvanced adenomas throughout the colon. Blinded and cross-validated test performance characteristics showed 88% sensitivity to advanced adenomas, 71% sensitivity to multiple non-advanced adenomas, and 72% specificity in the validation set. Conclusions: We demonstrate the viability of in vivo LEBS measurement of histologically normal rectal mucosa to predict the presence of clinically relevant adenomas throughout the colon. The current work represents the next step in the development of rectal LEBS as a tool for colorectal cancer risk stratification.

Original languageEnglish (US)
Pages (from-to)4347-4355
Number of pages9
JournalClinical Cancer Research
Volume21
Issue number19
DOIs
StatePublished - Oct 1 2015

Fingerprint

Adenoma
Colorectal Neoplasms
Colon
Mucous Membrane
Colonoscopy
Rectum
Cause of Death
Spectrum Analysis
Research Design
Cross-Sectional Studies
Logistic Models
Biopsy
Mortality
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Radosevic, A. J., Mutyal, N. N., Eshein, A., Nguyen, T. Q., Gould, B., Rogers, J. D., ... Roy, H. K. (2015). Rectal Optical Markers for in Vivo Risk Stratification of Premalignant Colorectal Lesions. Clinical Cancer Research, 21(19), 4347-4355. https://doi.org/10.1158/1078-0432.CCR-15-0136

Rectal Optical Markers for in Vivo Risk Stratification of Premalignant Colorectal Lesions. / Radosevic, Andrew J.; Mutyal, Nikhil N.; Eshein, Adam; Nguyen, The Quyen; Gould, Bradley; Rogers, Jeremy D.; Goldberg, Michael J.; Bianchi, Laura K.; Yen, Eugene F.; Konda, Vani; Rex, Douglas; Van Dam, Jacques; Backman, Vadim; Roy, Hemant K.

In: Clinical Cancer Research, Vol. 21, No. 19, 01.10.2015, p. 4347-4355.

Research output: Contribution to journalArticle

Radosevic, AJ, Mutyal, NN, Eshein, A, Nguyen, TQ, Gould, B, Rogers, JD, Goldberg, MJ, Bianchi, LK, Yen, EF, Konda, V, Rex, D, Van Dam, J, Backman, V & Roy, HK 2015, 'Rectal Optical Markers for in Vivo Risk Stratification of Premalignant Colorectal Lesions', Clinical Cancer Research, vol. 21, no. 19, pp. 4347-4355. https://doi.org/10.1158/1078-0432.CCR-15-0136
Radosevic, Andrew J. ; Mutyal, Nikhil N. ; Eshein, Adam ; Nguyen, The Quyen ; Gould, Bradley ; Rogers, Jeremy D. ; Goldberg, Michael J. ; Bianchi, Laura K. ; Yen, Eugene F. ; Konda, Vani ; Rex, Douglas ; Van Dam, Jacques ; Backman, Vadim ; Roy, Hemant K. / Rectal Optical Markers for in Vivo Risk Stratification of Premalignant Colorectal Lesions. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 19. pp. 4347-4355.
@article{09fa16100f8547519f4fd206ecee7cba,
title = "Rectal Optical Markers for in Vivo Risk Stratification of Premalignant Colorectal Lesions",
abstract = "Purpose: Colorectal cancer remains the second leading cause of cancer deaths in the United States despite being eminently preventable by colonoscopy via removal of premalignant adenomas. In order to more effectively reduce colorectal cancer mortality, improved screening paradigms are needed. Our group pioneered the use of low-coherence enhanced backscattering (LEBS) spectroscopy to detect the presence of adenomas throughout the colon via optical interrogation of the rectal mucosa. In a previous ex vivo biopsy study of 219 patients, LEBS demonstrated excellent diagnostic potential with 89.5{\%} accuracy for advanced adenomas. The objective of the current cross-sectional study is to assess the viability of rectal LEBS in vivo. Experimental Design: Measurements from 619 patients were taken using a minimally invasive 3.4-mm diameter LEBS probe introduced into the rectum via anoscope or direct insertion, requiring approximately 1 minute from probe insertion to withdrawal. The diagnostic LEBS marker was formed as a logistic regression of the optical reduced scattering coefficient μs ∗ and mass density distribution factor D. Results: The rectal LEBS marker was significantly altered in patients harboring advanced adenomas and multiple nonadvanced adenomas throughout the colon. Blinded and cross-validated test performance characteristics showed 88{\%} sensitivity to advanced adenomas, 71{\%} sensitivity to multiple non-advanced adenomas, and 72{\%} specificity in the validation set. Conclusions: We demonstrate the viability of in vivo LEBS measurement of histologically normal rectal mucosa to predict the presence of clinically relevant adenomas throughout the colon. The current work represents the next step in the development of rectal LEBS as a tool for colorectal cancer risk stratification.",
author = "Radosevic, {Andrew J.} and Mutyal, {Nikhil N.} and Adam Eshein and Nguyen, {The Quyen} and Bradley Gould and Rogers, {Jeremy D.} and Goldberg, {Michael J.} and Bianchi, {Laura K.} and Yen, {Eugene F.} and Vani Konda and Douglas Rex and {Van Dam}, Jacques and Vadim Backman and Roy, {Hemant K.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-15-0136",
language = "English (US)",
volume = "21",
pages = "4347--4355",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Rectal Optical Markers for in Vivo Risk Stratification of Premalignant Colorectal Lesions

AU - Radosevic, Andrew J.

AU - Mutyal, Nikhil N.

AU - Eshein, Adam

AU - Nguyen, The Quyen

AU - Gould, Bradley

AU - Rogers, Jeremy D.

AU - Goldberg, Michael J.

AU - Bianchi, Laura K.

AU - Yen, Eugene F.

AU - Konda, Vani

AU - Rex, Douglas

AU - Van Dam, Jacques

AU - Backman, Vadim

AU - Roy, Hemant K.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Purpose: Colorectal cancer remains the second leading cause of cancer deaths in the United States despite being eminently preventable by colonoscopy via removal of premalignant adenomas. In order to more effectively reduce colorectal cancer mortality, improved screening paradigms are needed. Our group pioneered the use of low-coherence enhanced backscattering (LEBS) spectroscopy to detect the presence of adenomas throughout the colon via optical interrogation of the rectal mucosa. In a previous ex vivo biopsy study of 219 patients, LEBS demonstrated excellent diagnostic potential with 89.5% accuracy for advanced adenomas. The objective of the current cross-sectional study is to assess the viability of rectal LEBS in vivo. Experimental Design: Measurements from 619 patients were taken using a minimally invasive 3.4-mm diameter LEBS probe introduced into the rectum via anoscope or direct insertion, requiring approximately 1 minute from probe insertion to withdrawal. The diagnostic LEBS marker was formed as a logistic regression of the optical reduced scattering coefficient μs ∗ and mass density distribution factor D. Results: The rectal LEBS marker was significantly altered in patients harboring advanced adenomas and multiple nonadvanced adenomas throughout the colon. Blinded and cross-validated test performance characteristics showed 88% sensitivity to advanced adenomas, 71% sensitivity to multiple non-advanced adenomas, and 72% specificity in the validation set. Conclusions: We demonstrate the viability of in vivo LEBS measurement of histologically normal rectal mucosa to predict the presence of clinically relevant adenomas throughout the colon. The current work represents the next step in the development of rectal LEBS as a tool for colorectal cancer risk stratification.

AB - Purpose: Colorectal cancer remains the second leading cause of cancer deaths in the United States despite being eminently preventable by colonoscopy via removal of premalignant adenomas. In order to more effectively reduce colorectal cancer mortality, improved screening paradigms are needed. Our group pioneered the use of low-coherence enhanced backscattering (LEBS) spectroscopy to detect the presence of adenomas throughout the colon via optical interrogation of the rectal mucosa. In a previous ex vivo biopsy study of 219 patients, LEBS demonstrated excellent diagnostic potential with 89.5% accuracy for advanced adenomas. The objective of the current cross-sectional study is to assess the viability of rectal LEBS in vivo. Experimental Design: Measurements from 619 patients were taken using a minimally invasive 3.4-mm diameter LEBS probe introduced into the rectum via anoscope or direct insertion, requiring approximately 1 minute from probe insertion to withdrawal. The diagnostic LEBS marker was formed as a logistic regression of the optical reduced scattering coefficient μs ∗ and mass density distribution factor D. Results: The rectal LEBS marker was significantly altered in patients harboring advanced adenomas and multiple nonadvanced adenomas throughout the colon. Blinded and cross-validated test performance characteristics showed 88% sensitivity to advanced adenomas, 71% sensitivity to multiple non-advanced adenomas, and 72% specificity in the validation set. Conclusions: We demonstrate the viability of in vivo LEBS measurement of histologically normal rectal mucosa to predict the presence of clinically relevant adenomas throughout the colon. The current work represents the next step in the development of rectal LEBS as a tool for colorectal cancer risk stratification.

UR - http://www.scopus.com/inward/record.url?scp=84945967448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945967448&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-0136

DO - 10.1158/1078-0432.CCR-15-0136

M3 - Article

C2 - 25991816

AN - SCOPUS:84945967448

VL - 21

SP - 4347

EP - 4355

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -